Therefore, these studies validated the immunotherapeutic effect of the drug in the breast tumor models, further identified the iron-laden macrophage populations as responsive to the CSF1R immunotherapy, and confirm their CSF1R status for future therapeutic targeting in human cancer. This evidence concerns the gene CSF1R and breast neoplasm.